Abstract：Objective To explore the application effect of perioperative iodine-free administration in patients with hyperthyroidism.Methods A total of 78 patients with hyperthyroidism who were treated in our hospital from October 2014 to December 2017 were selected as the research subjects.They were divided into the control group(n=39)and the observation group(n=39)according to the random number table method.In the control group,oral administration of iodine during perioperative period was used,and in the observation group,perioperative iodine-free was adopted.The related surgical indicators,serum free triiodothyronine(FT3)and serum free thyroxine(FT4)levels before and after treatment,incidence of complications after treatment was compared between the two groups.Results There were no significant differences in intraoperative blood loss or operation time between the two groups(P＞0.05).The hospital stay in the observation group after treatment was shorter than that in the control group,and the difference was statistically significant(P＜0.05).There were no significant differences in FT3 or FT4 level between the two groups after treatment(P＞0.05).After treatment,the symptoms of hoarseness,temporary parathyroid injury,and hypothyroidism in the observation group were lower than those in the control group,and the differences were statistically significant(P＜0.05).There were no significant differences in the levels of thyroid peroxidase antibody(TPOAb)or thyroglobulin antibody(TGAb)before treatment in the two groups(P＞0.05).After treatment,the TPOAb and TGAb indicators in the observation group were lower than those in the control group,and the differences were statistically significant(P＜0.05).Conclusion Perioperative iodine-free administration in patients with hyperthyroidism is feasible,and its routine indicators have not changed significantly,and complications have been reduced,which is worthy of promotion and application.
Felicetti F，Nervo A，Piovesan A，et al.Tyrosine kinase inhibitors rechallenge in solid tumors：a review of literature and a case description with lenvatinib in thyroid cancer[J].Expert Rev Anticancer Ther，2017，17（12）：1093-1098.
京公网安备 11010502046607号